NCT01516736 - Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim | Biotech Hunter

Enrollment

308

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

December 31, 2013

Conditions

Chemotherapy-induced NeutropeniaBreast Cancer

Interventions

DRUG

LA-EP2006

Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle LA-EP2006 is injected s.c. post chemotherapy application.

DRUG

Neulasta®

Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle Neulasta® is injected s.c. post chemotherapy application.

Trial Locations (53)

4000

Sandoz Investigational Site, San Miguel de Tucumán

11200

Sandoz Investigational Site, George Town

11600

Sandoz Investigational Site, George Town

15706

Sandoz Investigational Site, Santiago de Compostela

16150

Sandoz Investigational Site, Kelantan

23601

Sandoz Investigational Site, Newport News

28040

Sandoz Investigational Site, Madrid

38138

Sandoz Investigational Site, Germantown

40353

Sandoz Investigational Site, Mount Sterling

46014

Sandoz Investigational Site, Valencia

48202

Sandoz Investigational Site, Detroit

50024

Sandoz Investigational Site, Hyderabad

58501

Sandoz Investigational Site, Bismarck

67214

Sandoz Investigational Site, Wichita

71800

Sandoz Investigational Site, Kampung Baharu Nilai

71913

Sandoz Investigational Site, Hot Springs

72401

Sandoz Investigational Site, Jonesboro

92879

Sandoz Investigational Site, Corona

97401

Sandoz Investigational Site, Eugene

110092

Sandoz Investigational Site, Delhi

115478

Sandoz Investigational Site, Moscow